Sputnik V, Russia’s Covid-19 vaccine, has been found to demonstrate 97.2% efficacy against the coronavirus, the Russian Direct Investment Fund announced, citing data from the Republic of Belarus’ health ministry.

The  RDIF also said that no severe adverse events associated with the vaccination and no deaths related to the vaccination were observed, according to the data from Belarus.

The RDIF facilitated technology transfer to help in localising the production of Sputnik V vaccines in Belarus by the Belmedpreparaty company, which is successfully manufacturing the vaccine.Belarus, also a neighbour of Russia, was the first foreign country to register Sputnik V for the inoculation of its citizens against the Covid-19 pandemic.

In April 2021, the Belarusian health ministry authorised the shots produced in the country. Also, in the same month, Sputnik Light, the single dose vaccine, was also registered in Belarus.

“The Russian vaccine has demonstrated 97.2% efficacy against coronavirus in Belarus”. The RDIF also said that the data was based on results of over 860,000 people who were inoculated between January and July this year.

The  RDIF said in a statement on Wednesday, The efficacy of Sputnik V was measured based on data from more than 8,60,000 people vaccinated between January and July 2021,” .

Based  on real world data released by the health ministry of San Marino.In  the month, RDIF also said that the vaccine demonstrated an efficacy of 94.8% over 21 days after administering the first dose and 95.9% against hospitalizations.

The Gamaleya National Center of Epidemiology and Microbiology developed the Sputnik V vaccine with assistance from the RDIF, Russia’s sovereign wealth fund, which also markets the vaccine globally.

Dr Reddy’s Laboratories in India has received a nod from the subject expert committee of the Central Drugs Standard Control Organisation  to conduct phase 3 clinical trials for the Sputnik Light vaccine.

The two dose Sputnik V vaccine is one among the six shots that have been granted an emergency use approval  in India and is currently being used in the country’s Covid-19 vaccination drive.

LEAVE A REPLY

Please enter your comment!
Please enter your name here